Byron L Lam1, Janet L Davis2, Ninel Z Gregori2, Robert E MacLaren3, Aniz Girach4, Jennifer D Verriotto2, Belen Rodriguez2, Potyra R Rosa2, Xiaojun Zhang2, William J Feuer2. 1. Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: blam@med.miami.edu. 2. Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. 3. Nuffield Laboratory of Ophthalmology University of Oxford, and Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom. 4. Nightstar Therapeutics, London, United Kingdom.
Abstract
PURPOSE: To report the final results of a phase 2 high-dose gene therapy clinical trial in choroideremia. METHODS: Design: Phase 2 clinical trial. PARTICIPANTS: Six men (aged 32-72 years) with genetically-confirmed advanced choroideremia. Patients received subfoveal injection of AAV2-REP1 (1011 genome particles in 0.1 mL) in the worse-sighted eye. OUTCOME MEASURES: Primary measure was best-corrected visual acuity (BCVA) change from baseline in the treated eye compared to the untreated eye. Secondary endpoints included change from baseline in microperimetry, fundus autofluorescence, and spectral-domain optical coherence tomography (OCT). Safety evaluations included adverse events, viral shedding in body fluids, and vector antibody responses. RESULTS: Baseline mean ETDRS BCVA was 65.3 ± 8.8 (SD, range 56-77, 20/32-20/80) letters in the treated eyes and 77.0 ± 4.2 (69-81, 20/25-20/40) letters in the untreated eyes. At 2 years, 1 treated eye improved by 10 letters and another by 5 letters, while 1 untreated eye improved by 4 letters. All other eyes were within 2 letters of baseline. Baseline microperimetry sensitivities in the treated eyes were poor (1.2 ± 2.1 (0, 5.1) dB) and showed no significant change. No serious adverse event occurred. Two patients developed an atrophic retinal hole in a nonfunctioning macular area where baseline OCT showed preexisting thinning. Intraoperative microscope-integrated OCT allowed proper subretinal injection with avoidance of excessive foveal stretching and macular hole formation. CONCLUSIONS: Sustained improvement or maintenance of BCVA is achievable in choroideremia with high-dose AAV2-REP1, indicating BCVA is a viable primary outcome in advanced choroideremia. Choroideremia gene therapy delivered with intraoperative OCT has a good safety profile.
PURPOSE: To report the final results of a phase 2 high-dose gene therapy clinical trial in choroideremia. METHODS: Design: Phase 2 clinical trial. PARTICIPANTS: Six men (aged 32-72 years) with genetically-confirmed advanced choroideremia. Patients received subfoveal injection of AAV2-REP1 (1011 genome particles in 0.1 mL) in the worse-sighted eye. OUTCOME MEASURES: Primary measure was best-corrected visual acuity (BCVA) change from baseline in the treated eye compared to the untreated eye. Secondary endpoints included change from baseline in microperimetry, fundus autofluorescence, and spectral-domain optical coherence tomography (OCT). Safety evaluations included adverse events, viral shedding in body fluids, and vector antibody responses. RESULTS: Baseline mean ETDRS BCVA was 65.3 ± 8.8 (SD, range 56-77, 20/32-20/80) letters in the treated eyes and 77.0 ± 4.2 (69-81, 20/25-20/40) letters in the untreated eyes. At 2 years, 1 treated eye improved by 10 letters and another by 5 letters, while 1 untreated eye improved by 4 letters. All other eyes were within 2 letters of baseline. Baseline microperimetry sensitivities in the treated eyes were poor (1.2 ± 2.1 (0, 5.1) dB) and showed no significant change. No serious adverse event occurred. Two patients developed an atrophic retinal hole in a nonfunctioning macular area where baseline OCT showed preexisting thinning. Intraoperative microscope-integrated OCT allowed proper subretinal injection with avoidance of excessive foveal stretching and macular hole formation. CONCLUSIONS: Sustained improvement or maintenance of BCVA is achievable in choroideremia with high-dose AAV2-REP1, indicating BCVA is a viable primary outcome in advanced choroideremia. Choroideremia gene therapy delivered with intraoperative OCT has a good safety profile.
Authors: Liangbo L Shen; Aneesha Ahluwalia; Mengyuan Sun; Benjamin K Young; Holly K Grossetta Nardini; Lucian V Del Priore Journal: Ophthalmol Retina Date: 2020-03-14
Authors: Gabrielle D Lacy; Maria Fernanda Abalem; David C Musch; Kanishka T Jayasundera Journal: Ophthalmic Genet Date: 2020-02-26 Impact factor: 1.803
Authors: Kenneth C Fan; Nicolas A Yannuzzi; Nimesh A Patel; Catherin I Negron; Robert A Sisk; Aaron Nagiel; Audina M Berrocal Journal: Ophthalmol Retina Date: 2020-02-05
Authors: Gabrielle D Lacy; Maria Fernanda Abalem; Lilia T Popova; Erin P Santos; Gina Yu; Hanan Y Rakine; Julie M Rosenthal; Joshua R Ehrlich; David C Musch; K Thiran Jayasundera Journal: Ophthalmic Genet Date: 2020-06-22 Impact factor: 1.803
Authors: Sean M Crosson; Antonette Bennett; Diego Fajardo; James J Peterson; Hangning Zhang; Wei Li; Matthew T Leahy; Colin K Jennings; Ryan F Boyd; Sanford L Boye; Mavis Agbandge-McKenna; Shannon E Boye Journal: J Virol Date: 2021-03-03 Impact factor: 5.103
Authors: Alexandra V Garafalo; Artur V Cideciyan; Elise Héon; Rebecca Sheplock; Alexander Pearson; Caberry WeiYang Yu; Alexander Sumaroka; Gustavo D Aguirre; Samuel G Jacobson Journal: Prog Retin Eye Res Date: 2019-12-30 Impact factor: 21.198